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The cDNA of a Cat’-binding protein regucalcin was cloned from a rat liver cDNA library which was constructed in jlZAPI1 by immunoscreening. 
Positive clones were obtained from which spanned the region of interest, and they gave a sequence of 1.7 kb by sequencing with the dideoxynucle- 
otide method. Analysis of the sequence of the cloned cDNA showed that the cDNA encoded the complete amino acid sequence of the regucalcin 
molecule. Regucalcin was composed of 299 amino acid residues and its molecular weight was estimated to be 33,388 Da. The hydropathy profile 
of regucalcin showed a highly hydrophilic character. The nucleotide and amino acid sequences of regucalcin did not have statistically significant 
homology, as compared with the registered sequences which are found in the EMBL and GenBank databases containing several other Ca’+-binding 
proteins (calmodulin, calbindin-D28k and S-100s). The regucalcin molecule did not contain the EF-hand motif as a Ca2’-binding domain. The 
present study demonstrates that regucalcin is a unique Ca*‘-binding protein in the liver of rats. 
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1. INTRODUCTION 
Calcium ion (Ca”) plays a role as an important sec- 
ond messenger signal in a variety of pathways to pro- 
duce a Ca2’-mediated physiological responses in many 
cells. The Ca2+ signal is transmitted to an intracellular 
response partly via a family of Ca2+-binding proteins 
[l]. Recently, it has been reported that a novel Ca’+- 
binding protein regucalcin, which differs from calmod- 
ulin, is distributed in the hepatic cytosol of rats [2,3]. 
The isoelectric point of regucalcin was estimated as 
5.20, and the Ca2+-binding constant was found to be 
4.19 x 10’ M-’ by equilibrium dialysis [4]. This protein 
has a reversible effect on the activation and inhibition 
of various enzymes by Ca2’ in liver cells [4--6]. Regucal- 
tin may play a cell physiological role in the regulation 
of liver cell function related to Ca2’. 
On the other hand, the nucleotide and amino acid 
sequences of regucalcin have not been reported thus far. 
In the present study, therefore, we have attempted the 
cloning of a complementary deoxyribonucleic acid 
(cDNA) and the determination of a complete amino 
acid sequence for regucalcin in rat liver. It was found 
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that the regucalcin molecule consists of 299 amino acid 
residues and its sequence does not have significant ho- 
mology compared with the sequences of other proteins. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Deoxycytidine 5’-[a-‘?3]thiotriphosphate ([“SJdCTP; 37 TBql 
mmol) for DNA sequencing and nitrocellulose membrane (Hybond C) 
for immunoscreening were obtained from Amersham (Buckingham- 
shire, UK). Host bacterial cells (SURE Strain) and phages (native and 
R408 helper phage) were supplied by Stratagene (La Jolla, CA). All 
media used for the growth of bacteria and phage were purchased from 
Gibco Laboratories (Grand Island, NY). Reagents (analytical grade) 
and enzymes were obtained from Stratagene and Sigma Chemical Co. 
(St. Louis, MO). Any water and solutions used for the preparation of 
ribonucleic acid (RNA) were treated with chemical die- 
thylpyrocarbonate (DEPC, Sigma) to inhibit RNase activity. 
2.2. Isolation of RNA 
Total RNAs were prepared as described [7j. Liver was quickly 
removed from Wistar male rats (3-week-old; Japan SLC Inc., Hama- 
matsu, Japan), rinsed with ice-cold 0.25 M sucrose solution, and ho- 
mogenized in buffer solution containing 4 M guanidinium thiocya- 
nate, 25 mM sodium citrate (pH 7), 0.5% sarcosyl, 0.1 M 2-mercap- 
toethanol and 2 M sodium acetate. Total RNAs were extracted by 
vigorous shaking in a mixture of phenol, chloroform and isoamyl 
alcohol, and the phase was separated by centrifugation at 10,000 x g 
for 20 min at 4°C. RNA located in the aqueous phase was precipitated 
with isopropanol at -20°C. The RNA precipitate was pelleted by 
centrifugation, and the pellet was redissolved in 0.5% sodium dodecyl 
sulfate containing DEPC. The poly(A)’ RNA was purified by using 
oligo (dT)-cellulose column. 
2.3. Construction of rat liver cDNA library 
The first strand of cDNA was synthesized from 5 ,ug poly(A)’ RNA 
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using 50 units Moloney-Murine Leukemia Virus Reverse Transcrip- 
tase (M-MuLVRT), and oligo (dT),, primer-linker which has XhoI 
restriction enzyme recognition site. Double-stranded cDNA was gen- 
erated by replacement synthesis with E. coli RNase H and DNA 
polymerase I [S]. After an EcoRI adaptor was added, cDNA was 
ligated with the XhoI-EcoRI-digested phage expression vector, a 
aZAP (Stratagene) [9], and subsequently packaged into native 
phages using in vitro packaging extracts. 
2.4. Screening of library 
Nitrocellulose membranes (Hybond C) were soaked with 10 mM 
isopropyl-thio-p-o-galactoside (IPTG) and dried. Approximately 
1 x IO6 phage of a rat liver cDNA library were plated onto 20 dishes 
(diameter 140 mm). After 3.5 h preincubation at 42’C, the dishes were 
overlayed with the pretreated membranes and incubated for an addi- 
tional 3.5 h at 37°C. The removed membranes were incubated with 
rabbit-anti-regucalcin antiserum (1 : 200 dilution) [lo] for 120 min. 
Membranes were then incubated with an anti-rabbit second antibody 
conjugated to alkaline phosphatase, and finally developed using 0.35 
mM nitro blue tetrazolium (NBT) and 0.4 mM 5-bromo-4-chloro-3- 
indolyl phosphate (BCIP). 
2.5. In vivo excision 
As a part of cDNA is located in the plasmid Bluescript within the 
phage vector, an automatic excision of the Bluescript vector instead 
of the subcloning was performed according to the method described 
in an instruction manual of jlZAPI1 [9]. The purified phage lysate 
combined with E. coli SURE cells was mixed with R408 helper phage 
and incubated. To obtain the excised Bluescript, the excised DNA was 
infected with SURE cells and plated for selection on LB plates con- 
taining ampicillin (50 &ml). 
2.6. DNA sequencing 
Nucleotide sequencing was performed by the method of dideoxynu- 
cleotide termination [l l] using the Sequenase system (US Biochemical 
Corp. Cleveland, OH) with 3 pg denatured ouble-stranded DNA as 
a template [12]. The cDNA clones were sequenced from both direc- 
tions by the overlapping manner after characterization by restriction 
enzyme analysis. The sequences of cDNA were assembled and ana- 
lyzed by the GENETYX program (SDC Inc., Tokyo). 
3. RESULTS 
Messenger RNA was isolated from the liver of male 
Wistar rats by using guanidium thiocyanate and oligo 
(dT) chromatography. The Poly(A)’ RNA (5 pg), con- 
taining sizes in the range of 0.3-4.3 kb, was used for the 
AZAPII cloning system. By the enzymatic reaction with 
reverse transcriptase, the cDNA library which consists 
of 3.2 x 10’ independent clones was obtained. Using a 
rabbit-anti-regucalcin antiserum, 14 immunoreactive 
clones were detected after the first screening for 1 x lo6 
recombinant plaques. Finally, eight positive clones were 
obtained by repeated immunoscreening. The inserts of 
eight clones obtained from the cDNA library were iden- 
tified, and the insert size of the cDNA was 1.70 kb. This 
cDNA of 1.70 kb contained a complete open reading 
frame of 0.897 kb which is the cDNA encoding a mole- 
cule of regucalcin, as shown in Fig. 1. 
The context surrounding the ATG codon signaling 
the start of translation, was as defined by Kozak 
[GCCA(or G)CCmG] [13]. The translation start site 
(GCGACCmT) in the 5’-noncoding region of the 
regucalcin nucleotide was fitted to the consensus se- 
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quence for translation start as defined by Kozak. Thus, 
we chose methionine as a position 1 of the amino acid 
sequence of regucalcin (Fig. 1). The number of amino 
acids in regucalcin as predicted from the nucleotide was 
299. The molecular mass of the predicted amino acid 
sequence was calculated to be 33,388 Da. The amino 
acid composition of regucalcin is summarized in Table 
I, and shows that regucalcin has a relatively higher con- 
tent of glycine, valine, asparatic acid and serine. 
The hydropathy profile of regucalcin was calculated 
according to the method of Kyte and Doolittle [ 141. This 
result is shown in Fig. 2. There was a hydrophobic 
sequence in both N-terminal and C-terminal regions of 
the regucalcin molecule. However, regucalcin showed a 
hydrophilic character as a molecule. 
4. DISCUSSION 
The present study was undertaken to characterize the 
molecular structure of regucalcin. From rat liver 
regucalcin cDNA cloning, a cDNA clone with an insert 
of 1.7 kb was obtained. Northern hybridization of rat 
liver mRNA with the obtained regucalcin cDNA probe 
gave a definite band of about 1.7 kb confirming the 
full-length size of the regucalcin cDNA clone, as re- 
ported previously [15,16]. The amino acid sequence de- 
duced from the regucalcin cDNA coincided completely 
with the amino acid sequence of regucalcin as analyzed 
by digestion with proteases. Moreover, the molecular 
mass of regucalcin consisted of 299 amino acid residues 
and was calculated to be 33,388 Da. This value was 
fitted in the result estimated by SDS-polyacrylamide gel 
electrophoresis for regucalcin (data not shown). Also, 
it is known that the isoelectric point (PI) of regucalcin 
is 5.20 [4]. This coincided with the p1 of the deduced 
amino acid sequence. Thus, regucalcin was coded from 
the obtained cDNA clone. 
The nucleotide sequence from cDNA cloning for 
regucalcin was compared to that of other proteins. A 
computer-assisted search (FASTA) [17] of the nucleo- 
tide sequence of rat liver regucalcin showed that the 
nucleotide sequence did not have statistically significant 
homology with the registered sequences which are 
found in the EMBL and GenBank databases. More- 
over, the predicted amino acid sequence of regucalcin did 
not have significant homology with several other Ca”- 
binding proteins; regucalcin had low homology for 
calmodulin [18], calbindin-D28k [19], and S-100/? [20] 
with homologies of 13.3, 16.3 and 11 .O%, respectively. 
These values from the best homology matching for 
amino acid sequences were obtained by the introduction 
of gaps to maximize homology. In fact, the homology 
was only slight. Thus, regucalcin is a novel protein, and 
it entirely differs from other Ca2’-binding proteins. 
Furthermore, regucalcin showed a hydrophilic char- 
acter. In particular, regucalcin had comparatively 
higher hydrophilic regions at positions between 100 and 
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TCGATCCTCCACTCTTTCCTTTGTCTTCTATTTTAAAGATATCTTGAAAAAAACCTGTCACTGTCCTTTTCCTGCGACC 
ATC. TCT. TCC. ATC. AAC. ATT. CAA. TCT.CTT. TTA. ACC.CAG. AAC. TAC. ACC. TCT.GCC.GAG. TCC. CCT. 
let-Ser-Ser-Ile-Lys-Ile-Glu-Cys-Val-L~~-Arg-Glu-Asn-Tyr-Arg-Cys-Gly-Glu-Ser-P~~- 
GTG. TGG.GAG.GAG.GCA. TCA. AAG. TGT. CTG. CTG. TTT.GTA.GAC. ATC. CCT. TCA. AAG. ACT.CTC. TGC. 
Val-Trp-Glu-Glu-Ala-Ser-Lys-Cys-Leu-L~~-Phe-Val-Asp-Ile-Pro-Ser-Lys-Thr-Val-Cys- 
40 
CGA. TGG.GAT. TCG. ATC. AGC. AAT. CGA.GTG. CAG. CGA. GTT.CGT. GTA.GAT.GCC.CCA.GTC. ACT. TCA. 
Arg-Trp-Asp-Ser-Ile-Ser-Asn-Arg-Val-G~~-Arg-Val-Gly-Val-Asp-Ala-Pro-Val-Ser-S~~- 
GTG.GCA. CTT. CGA. CAG. TCA.GGA. CCC. TAT. CTT. CCC. ACC. ATT.GGA. ACC. AAG. TTC. TGT. GCT. TTG. 
Val-Ala-Leu-Arg-Gln-Ser-Gly-Gly-Tyl-V~~-Ala-Thr-Ile-Gly-Thr-Lys-Phe-Cys-Ala-L~~- 
AAC. TGG. GAA. CAT. CAA. TCA. CTA. TTT. ATC. CTA. GCC. ATG. GTG. GAT.GAA. CAT. AAG. AAA. AAC. AAT. 
Asn-Trp-Glu-Asp-Gln-Ser-VaI-Phe-Ile-L~~-Ala-Met-Val-Asp-Glu-Asp-Lys-Lys-Asn-Asn- 
100 
CGA. TTC. AAT. CAT. CCC. AAG. GTG. CAT. CCT. GCT. GGG. AGA. TAC. TTT. GCT. GGT. ACC. ATG. GCT. GAG. 
Arg-Phe-Asn-Asp-Gly-Lys-Val-Asp-Pro-~~~-Gly-Arg-Tyr-Phe-Ala-Gly-Thr-Met-Ala-~~~- 
GAA. ACC. CCC. CCA. GCT. GTT. CTG. GAG. CGG. CAC. CAA. GGG. TCC. TTG. TAC. TCC. CTT. TTT. CCT. GAT. 
Glu-Thr-Ala-Pro-Ala-Val-Leu-Glu-Arg-~~~-Gln-Gly-Ser-Leu-Tyr-Ser-Leu-Phe-Pro-~~~- 
CAC. ACT. GTG. AAG. AAA. TAC. TTT. AAC. CAA. GTG. GAT. ATC. TCC. AAT.GGT. TTG.GAT. TGG. TCC. CTG. 
His-Ser-Val-Lys-Lys-Tyr-Phe-Asn-Gln-~~~-Asp-Ile-Ser-Asn-Gly-Leu-Asp-Trp-Ser-~~~- 
CAC. CAT. AAA. ATC. TTC. TAC. TAC. ATT.GAC. AGC. CTG. TCC. TAC. ACT.GTG.GAT.GCC. TTT.GAC. TAT. 
Asp-His-Lys-Ile-Phe-Tyr-Tyr-Ile-Asp-~~~-Leu-Ser-Tyr-Thr-Val-Asp-Ala-Phe-Asp-T r- 
Ii;0 
GAC. CTG. CCA. ACA.GGA. CAG. ATT. TCC. AAC. CGC. AGG. ACT. GTT. TAC. AAG. ATG. GAA. AAA. CAT. GAA. 
Asp-Leu-Pro-Thr-Gly-Gln-Ile-Ser-Asn-~~~-Arg-Thr-Val-Tyr-Lys-~et-Glu-Lys-Asp-~~~- 
CAA. ATC. CCA. CAT. CGA. ATG. TGC. ATT. GAT. GTT. GAG.GGG. AAG. CTT. TGG. GTG. CCC. TGT. TAC. AAT. 
Gln-Ile-Pro-Asp-Gly-Met-Cys-Ile-Asp-~~~-Glu-GIy-Lys-Leu-Trp-Val-Ala-Cys-Tyr-~~~- 
GGA.GGA. AGA.GTA. ATT. CCC. CTA.GAT. CCT. GAG. ACA.GGG. AAA. AGA. CTG. CAA. ACT.GTG. AAG. TTG. 
Gly-Gly-Arg-Val-Ile-Arg-Leu-Asp-Pro-~~~-Thr-Gly-Lys-Arg-Leu-Gln-Thr-Val-Lys-~~~- 
CCT.GTT.GAT. AAA. ACA. ACT. TCA. TGC. TGC. TTT. GGA.GGG. AAG. GAT. TAC. TCT. GAA. ATG. TAC. GTG. 
Pro-Val-Asp-Lys-Thr-Thr-Ser-Cys-Cys-~~~-Gly-Gly-Lys-Asp-Tyr-Ser-Glu-Met-Tyr-Val- 
260 
ACA. TGT.GCC. AGG.GAT. GGG. ATG. AGC.GCC. GAA.GGT. CTT. TTG. AGG. CAG. CCT. GAT. GCT. GGT. AAC. 
Thr-Cys-Ala-Arg-Asp-Gly-Met-Ser-Ala-~~~-Gly-Leu-Leu-Arg-Gln-Pro-Asp-Ala-Gly-~~~- 
ATT. TTC. AAG. ATA. ACA.GGT. CTT. CCC. GTC. AAA. CGA. ATT. GCT. CCA. TAT. TCC. TAT. GCA. CCC. TAA 
Ile-Phe-Lys-Ile-Thr-Gly-Leu-Gly-Val-~~~-Gly-Ile-Ala-Pro-Tyr-Ser-Tyr-Ala-Gly-~~~ 
ACTGCAGCTCTTCCTTGCTGTCAGAAGAAAAAGCTTGAAGACAACTGAGAATTAAACTGCAGCTCTTCCTTGCTGTCAG 
AAGAAAAAGCTTGAAGACAACTGAGAATTAAGGGAGAGAAATCAATGAACTTTCATATTGTTTTTTTAATGAGGCAGTG 
ATATTGACATGGTTAAACTGCTTTAATTTACACTTTTGATTGGGTGCTGGGGAATAAACCTAAAGCCATGGCATATTAA 
Fig. 1. Nucleotide and deduced amino acid sequences of the rat regucalcin cDNA. The predicted amino acid sequence was presented below the 
nucleotide sequence. The numbers in the sequence refer to the positions of amino acids; position 1 represents methionine (Met) residue. The 
termination codon (fAA) was indicated by ***. The putative polyadenylation signal AATAAA is underlined. 
200 of the amino acid sequence. This hydrophilic region binding of Ca2’. Many Ca2’-binding proteins have the 
may be a functional domain which is related to the common structural feature of an EF-hand, which binds 
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200 300 
Residue number 
Fig. 2. Hydropathy profiles of rat regucalcin. Hydropatby analysis was performed according to Kyte and Doolittle for the 11 amino acid residues. 
The N-terminal was on the left and the C-terminal was on the right of the figure. Area of relative hydrophobic&y or hydrophilicity was seen the 
above or below of horizontal line in the figure, respectively. 
Ca” [21]. The S-100 protein has two EF-hands in the 
region with a relatively high hydrophili~ity @2]. The 
most common EF-hand is composed of the helix-loop- 
helix-domain. The prototype loop consists of 12 amino 
acids, of which five have a carboxyi (or a hydroxyl 
group) in their side chain, precisely spaced so as to 
coordinate the Ca2’ [23]. Analysis of the structure of the 
EF-hand from the regucalcin sequence did not give the 
expected pattern of amino acids conforming to the typ- 
ical EF-hand structure of a Ca*‘-binding site. Regucal- 
tin may differ from a Ca’+-binding protein of the EF- 
hand type, although further investigation is required to 
Table I 
Ammo acid composition of regucalcin from rat liver 
Amino acid Mol residue/m01 
protein 
Ratio (%) 
Alanine 18 6.02 
Arginine 16 5.35 
Asparagine 11 3.68 
Aspartic acid 24 8.03 
Cysteine 10 3.34 
Glutamine 9 3.01 
Glutamic acid 16 5.35 
Glycine 25 8.36 
Histid~e 3 1.00 
Isoleucine 16 5.35 
Leucine 20 6.69 
Lysine 19 6.35 
Methionine I 2.34 
Phenylalanine 11 3.68 
Proline 12 4.01 
Serine 23 7.69 
Threonine 14 4.68 
Tryptophan 5 1.67 
Tyrosine 1.5 5.02 
Valine 25 8.36 
identify the sites of Ca2’-binding, Further analysis sug- 
gests that the regucalcin sequence does not contain a 
potential N-linked glycosylation site (Asn-X-Ser (or 
Thr)] [24]. 
In conclusion, we have identified a regucalcin cDNA 
encoding a complete regucalcin molecule, and have de- 
termined the primary structure of regucalcin. Regucal- 
tin may be a unique Ca2’-binding protein. 
Ackrzow~edgemen~: We would like to thank Dr. Yasuhiro Tomooka 
(Institute of Physical and Chemical Research, Japan) for helping us 
with the homology search of regucalcin cDNA and Dr. Mituo Hayashi 
(Asahi Chemical Industry Co., Ltd., Japan) for excellent help in amino 
acid analysis of regucalcin. 
REFERENCES 
Ill 
PI 
131 
I41 
151 
t61 
PI 
IsI 
[91 
WI 
u 11 
[I21 
Wasserman, R.H. (1991) in: Novel Calcium-Binding Proteins 
(C.W. Heizmann, Ed.), pp. 7-12, Springer, Berlin. 
Yamaguchi, M. and Yamamoto, T. (1978) Chem. Pharm Bull. 
26, 1915-1918. 
Yamaguchi, M. and Sugii, K. (1981) Chem. Pharm. Bull. 29, 
567-570. 
Yamaguchi, M. (1992) in: Calcium Inhibition (K. Kohama, Ed.), 
pp. 19-41, Japan Sci. Sot. Press, Tokyo and CRC Press, Boca 
Raton. 
Yamaguchi, M. and Sakurai, T. (1991) FEBS Lett. 279,281-284. 
Yamaguchi, M. and Tai, H. (1991) Mol. Cell B&hem. 106, 
25-30. 
Chomczynski, P. and Sacchi, N. (1987) Anal. B&hem. 162, 156 
159. 
Gubler, U. and Hoffman, B.J. (1983) Gene 25, 263-269. 
Short, J.M., Fernandez, J.M., Sorge, J.A. and Huse, W.D. (1988) 
Nucleic Acids Res. 16, 7583-7600. 
Yamaguchi, M. and Isogai, M. (1993) Mol. Cell Biochem. (in 
press). 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. 
Acad. Sci. USA 74, 546M467. 
Hattori, M. and Sakaki, Y. (1986) Anal. B&hem. 152,232.-238. 
Volume 327, number 3 FEBS LETTERS August 1993 
[13] Kozak, M. (1987) Nucleic Acids Res. 15, 8125-8132. 
[14] Kyte, J. and Doolittle, R. (1982) J. Mol. Biol. 157, 105-132. 
[15] Shimokawa, N. and Yamaguchi, M. (1992) FEBS Lett. 305,151- 
154. 
[16] Shimokawa, N. and Yamaguchi, M. (1993) FEBS Lett. 316,79- 
[17] zpman. D.J. and Pearson, W.R. (1985) Science 227, 1435-1441. 
[18] Nojima, H. and Sokabe, H. (1987) J. Mol. Biol. 193, 439445. 
[19] Yamakuni, T., Kuwano, R., Odani, S., Miki, N., Yamaguchi, Y. 
and Takahashi, Y. (1986) Nucleic Acids Res. 14, 6768. 
[20] Isobe, T. and Okuyama, T. (1978) Eur. J. Biochem. 89,379-388. 
[21] Tufty, R.M. and Kretsinger, R.H. (1975) Science 187, 167-169. 
[22] Hilt, DC. and Kligman, D. (1991) in: Novel Calcium-Binding 
Proteins (C.W. Heizmann, Ed.), pp. 65-103, Springer, Berlin. 
[23] Heizmann, C.W. and Hunziker, W. (1991) Trends Biochem. Sci. 
16, 98-103. 
[24] Marshall, R.D. (1972) Annu. Rev. B&hem. 41, 673-702. 
255 
